GSK vs. AZN.L
Compare and contrast key facts about GlaxoSmithKline plc (GSK) and AstraZeneca plc (AZN.L).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GSK or AZN.L.
Correlation
The correlation between GSK and AZN.L is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
GSK vs. AZN.L - Performance Comparison
Key characteristics
GSK:
-0.21
AZN.L:
-0.48
GSK:
-0.12
AZN.L:
-0.49
GSK:
0.99
AZN.L:
0.93
GSK:
-0.19
AZN.L:
-0.43
GSK:
-0.34
AZN.L:
-0.86
GSK:
16.11%
AZN.L:
13.30%
GSK:
26.51%
AZN.L:
24.60%
GSK:
-55.21%
AZN.L:
-49.99%
GSK:
-15.61%
AZN.L:
-20.52%
Fundamentals
GSK:
$75.93B
AZN.L:
£161.22B
GSK:
$1.65
AZN.L:
£3.39
GSK:
22.73
AZN.L:
30.68
GSK:
0.36
AZN.L:
0.99
GSK:
2.42
AZN.L:
2.98
GSK:
4.19
AZN.L:
6.16
GSK:
$24.01B
AZN.L:
£41.39B
GSK:
$16.98B
AZN.L:
£33.41B
GSK:
$5.14B
AZN.L:
£12.65B
Returns By Period
In the year-to-date period, GSK achieves a 11.89% return, which is significantly higher than AZN.L's 0.80% return. Over the past 10 years, GSK has underperformed AZN.L with an annualized return of 2.53%, while AZN.L has yielded a comparatively higher 12.07% annualized return.
GSK
11.89%
-2.30%
2.01%
-4.78%
1.57%
2.53%
AZN.L
0.80%
-7.41%
-9.09%
-11.72%
7.30%
12.07%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GSK vs. AZN.L — Risk-Adjusted Performance Rank
GSK
AZN.L
GSK vs. AZN.L - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and AstraZeneca plc (AZN.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GSK vs. AZN.L - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 4.15%, more than AZN.L's 2.36% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 4.15% | 4.60% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% |
AZN.L AstraZeneca plc | 2.36% | 2.23% | 2.21% | 1.98% | 2.33% | 2.95% | 2.87% | 3.44% | 4.28% | 4.50% | 3.95% | 3.73% |
Drawdowns
GSK vs. AZN.L - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.21%, which is greater than AZN.L's maximum drawdown of -49.99%. Use the drawdown chart below to compare losses from any high point for GSK and AZN.L. For additional features, visit the drawdowns tool.
Volatility
GSK vs. AZN.L - Volatility Comparison
The current volatility for GlaxoSmithKline plc (GSK) is 11.15%, while AstraZeneca plc (AZN.L) has a volatility of 15.65%. This indicates that GSK experiences smaller price fluctuations and is considered to be less risky than AZN.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
GSK vs. AZN.L - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and AstraZeneca plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities